Trouble viewing this email?  View in web browser ›

The Wall Street Journal logo The Wall Street Journal logo
WSJ News Debrief
WSJ News Debrief

In this edition: This week we look at a fast-spreading and deadly fungus, the cause of Beethoven’s medical issues and coffee’s health effects

 

In the News

BSIP/UNIVERSAL IMAGES GROUP VIA GETTY IMAGES

Deadly fungus advances across the U.S. Candida auris, a fungus discovered about 15 years ago in Japan, infected at least 2,377 people in the U.S. in 2022, up from 53 in 2016, the Centers for Disease Control and Prevention said. Read more.

  • Dangerous Fungi Spread As World Temperatures Rise (Read)
  • What We Know About Deadly Fungal Infections (Read)

FDA may authorize spring Covid boosters. Agency officials could within weeks clear giving a second dose of the updated, Omicron-targeting boosters to the elderly and immunocompromised, people familiar with the agency's deliberations told The Wall Street Journal. Read more.

What sickened Beethoven? A genetic analysis of samples of Beethoven's hair saved over the centuries fingered Hepatitis B as a source of the composer's health woes. The analysis also revealed unexpected findings about Beethoven’s ancestry. Read more.

Personalized stem-cell therapies. Researchers are planning human tests of treatments consisting of stem cells created by reverse-engineering a patient’s own cells back to a stem-cell state. The hope is such therapies can treat diseases like macular degeneration and congenital heart disease. Read more.

 

The Big Number

2.8

Percent of 8-year-olds diagnosed with autism spectrum disorder in 2020, according to the CDC

 

Quoted

“We need to pay attention that we aren’t running into a situation where tech companies sell black-box algorithms that determine parts of our lives.”

— Gerd Gigerenzer, director of the Harding Center for Risk Literacy at the University of Potsdam in Germany
 

Your Well-Being

SEBASTIAN GOLLNOW/DPA/ZUMA PRESS

That cup of Joe may not be as unhealthy as feared. A mug of America's favorite stimulant each day may not be bad for the heart after all, researchers reported. But the beverage did reduce the sleep of subjects in the randomized controlled trial. Read more.

For perimenopausal women, the brain fog is real--and temporary. About 60% of women in their 40s and early 50s report a decline in memory function, but their cognitive performance stays within a normal range and memory issues often resolve upon reaching menopause. Read more.

  • Drugs Are In the Works to Treat the Depression and Anxiety That Many Women Experience During Perimenopause (Read)

Contaminated eye drops linked to three deaths. Another six people who used the EzriCare and Delsam Pharma LLC’s Artificial Tears eye drops have experienced vision loss. The manufacturer recalled the drops last month. Read more.

  • EzriCare Eye Drops Recalled After CDC Linked Them to Infections (Read)
 

The Business of Health

PETER BYRNE/ZUMA PRESS

Moderna Prices Its Covid Vaccine at $130 a Dose. The vaccine's price will be several times higher than the $15 to $26 a dose the federal government has paid, when sales shift to the commercial market later this year, sparking criticism from some Senators. Read more.

  • Pfizer Targeting Covid Vaccine Price of $110 to $130 a Dose (Read)
 

About Us

This newsletter was compiled by the WSJ’s Health & Science team. Follow us on Twitter @WSJHealth and @WSJScience. Email us by replying to this newsletter.

 
Share this email with a friend.
Forward ›
Forwarded this email by a friend?
Sign Up Here ›
 
Desktop, tablet and mobile. Desktop, tablet and mobile.
Access WSJ‌.com and our mobile apps. Subscribe
Apple app store icon. Google app store icon.
Unsubscribe   |    Newsletters & Alerts   |    Contact Us   |    Privacy Notice   |    Cookie Notice
Dow Jones & Company, Inc. 4300 U.S. Ro‌ute 1 No‌rth Monm‌outh Junc‌tion, N‌J 088‌52
You are currently subscribed as [email address suppressed]. For further assistance, please contact Customer Service at sup‌port@wsj.com or 1-80‌0-JOURNAL.
Copyright 2023 Dow Jones & Company, Inc.   |   All Rights Reserved.
Unsubscribe